01—Abstract
Summary
Summary of the 10-K filed February 27, 2015. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. (ZTS) reported strong performance for the fiscal year ended December 31, 2014, marking its first full year as an independent public company following its separation from Pfizer in early 2013.
The company demonstrated robust revenue growth of 5% year-over-year, reaching $4.79 billiona, driven by solid operational performance across its global segments, particularly in the United States and emerging markets. This growth was fueled by both increased sales volume and price increases, supported by a diverse product portfolio targeting both livestock and companion animals. Key financial highlights include a 16% increase in Net Income Attributable to Zoetis, reaching $583 million.
The company also reported a strong adjusted net income of $790 millionb, indicating effective management of operational costs and strategic investments in research and development. Zoetis's strategic focus on expanding its presence in emerging markets and developing new products, coupled with its established market leadership and customer relationships, positions it well for continued growth. The company's diversified revenue streams and focus on innovation in animal health medicine and vaccines present a stable and promising outlook for investors.
02—Key points
Key Highlights
- Revenue increased by 5% to $4.79 billion in 2014, driven by operational growth across all segments, particularly the U.S. and emerging markets.
- Net income attributable to Zoetis rose by 16% to $583 million.
- Adjusted net income, a non-GAAP measure used by management, increased by 11% to $790 million.
- Livestock product revenue grew by 6% operationally, driven by strong performance in cattle, swine, and poultry portfolios.
- Companion animal product revenue increased by 3% operationally, bolstered by new product launches like Apoquel®.
- The company maintained a significant focus on R&D, with expenses of $396 million in 2014, supporting both new product development and product lifecycle enhancements.
- Zoetis continued its strategic expansion in emerging markets, which contributed 24% of total revenue in 2014.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 27, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $4.79B$4.56B | +4.9% |
| Cost of Revenue | $1.72B$1.67B | +2.9% |
| Gross Profit | $3.07B$2.89B | +6.1% |
| SG&A Expenses | $1.64B$1.61B | +1.9% |
| Interest Expense | $117.00M$113.00M | +3.5% |
| Net Income | $587.00M$503.00M | +16.7% |
| EPS (Basic) | $1.16$1.01 | +14.9% |
| EPS (Diluted) | $1.16$1.01 | +14.9% |
| Shares Outstanding (Basic) | 501.06M500.00M | +0.2% |
| Shares Outstanding (Diluted) | 502.02M500.32M | +0.3% |
05—Questions
Frequently Asked Questions
What was Zoetis's revenue and net income performance in 2014?
Zoetis reported total revenue of $4.79 billion, a 5% increase from 2013. Net income attributable to Zoetis was $583 million, a 16% increase year-over-year. Adjusted net income, a non-GAAP measure, was $790 million, up 11%.
What are the main drivers of Zoetis's revenue growth?
Revenue growth was driven by a combination of higher sales volume (5%) and price increases (2%), with contributions from both livestock (6% operational growth) and companion animal (3% operational growth) segments. Key markets contributing to growth included the United States and emerging markets.
How is Zoetis investing in future growth?
Zoetis continues to invest significantly in research and development, spending $396 million in 2014. The company focuses on developing new products and enhancing existing ones through product lifecycle development, with a strategic emphasis on expanding its presence and offerings in emerging markets.
What is Zoetis's dividend policy?
Zoetis initiated a quarterly cash dividend in 2013 and continued to pay dividends throughout 2014. The Board of Directors declared quarterly dividends of $0.072 per share in 2014. The company intends to continue paying quarterly dividends, subject to Board approval and financial performance, but expects to retain most future earnings for business development and expansion.
06—Continue